Prior to the 2018 CRISPR controversy involving the genetically modified twins, China's biotech regulations lagged behind the swift progress in the sector. Faced with international criticism following the incident, China overhauled its strategy by incorporating genetic research protocols into the Civil Code, establishing the National Science and Technology Ethics Committee, and enhancing regulations on human gene and embryo experimentation. Volume XLVII staff editor Vivikth Vemula contends that while these changes align China more with Western perspectives on genome editing, their true efficacy is yet to be seen. This post explores the comprehensive overhaul and adjustments made to China's biotechnology regulatory regime, particularly focusing on human genome editing.
Read More